Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/86417
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study
Author: Thakkar, V.
Stevens, W.
Prior, D.
Youssef, P.
Liew, D.
Gabbay, E.
Roddy, J.
Walker, J.
Zochling, J.
Sahhar, J.
Nash, P.
Lester, S.
Rischmueller, M.
Proudman, S.
Nikpour, M.
Citation: Arthritis Research & Therapy, 2013; 15(6):R193-1-R193-11
Publisher: BioMed Central
Issue Date: 2013
ISSN: 1478-6362
1478-6362
Statement of
Responsibility: 
Vivek Thakkar, Wendy Stevens, David Prior, Peter Youssef, Danny Liew, Eli Gabbay, Janet Roddy, Jennifer G Walker, Jane Zochling, Joanne Sahhar, Peter Nash, Susan Lester, Maureen Rischmueller, Susanna M Proudman, and Mandana Nikpour
Abstract: Introduction: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc). Screening guidelines for PAH recommend multiple investigations, including annual echocardiography, which together have low specificity and may not be cost-effective. We sought to evaluate the predictive accuracy of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in combination with pulmonary function tests (PFT) (‘proposed’ algorithm) in a screening algorithm for SSc-PAH. Methods: We evaluated our proposed algorithm (PFT with NT-proBNP) on 49 consecutive SSc patients with suspected pulmonary hypertension undergoing right heart catherisation (RHC). The predictive accuracy of the proposed algorithm was compared with existing screening recommendations, and is presented as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Results: Overall, 27 patients were found to have pulmonary hypertension (PH) at RHC, while 22 had no PH. The sensitivity, specificity, PPV and NPV of the proposed algorithm for PAH was 94.1%, 54.5%, 61.5% and 92.3%, respectively; current European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines achieved a sensitivity, specificity, PPV and NPV of 94.1%, 31.8%, 51.6% and 87.5%, respectively. In an alternate case scenario analysis, estimating a PAH prevalence of 10%, the proposed algorithm achieved a sensitivity, specificity, PPV and NPV for PAH of 94.1%, 54.5%, 18.7% and 98.8%, respectively. Conclusions: The combination of NT-proBNP with PFT is a sensitive, yet simple and non-invasive, screening strategy for SSc-PAH. Patients with a positive screening result can be referred for echocardiography, and further confirmatory testing for PAH. In this way, it may be possible to shift the burden of routine screening away from echocardiography. The findings of this study should be confirmed in larger studies.
Keywords: Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Natriuretic Peptide, Brain; Peptide Fragments; Respiratory Function Tests; Sensitivity and Specificity; Cohort Studies; Algorithms; Aged; Middle Aged; Female; Male
Rights: © 2013 Thakkar et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
RMID: 0020137114
DOI: 10.1186/ar4383
Grant ID: http://purl.org/au-research/grants/nhmrc/1038612
Appears in Collections:Public Health publications

Files in This Item:
File Description SizeFormat 
hdl_86417.pdfPublished version408.24 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.